Cargando…
The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis
BACKGROUND: Despite recent advancements in surgical techniques, chemotherapy, and radiotherapy, the 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) remains an unsatisfactory ~8%. MATERIAL/METHODS: Data were extracted to identify patients with non-metastatic pancreatic a...
Autores principales: | Li, Yuqiang, Liu, Wenxue, Zhao, Lilan, Xu, Yang, Yan, Tingyu, Yang, Qionghui, Pei, Qian, Güngör, Cenap |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212811/ https://www.ncbi.nlm.nih.gov/pubmed/32358953 http://dx.doi.org/10.12659/MSM.921515 |
Ejemplares similares
-
Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis
por: Wang, Dan, et al.
Publicado: (2020) -
The survival impact of palliative radiotherapy on synchronous metastatic pancreatic ductal adenocarcinoma: metastatic site can serve for radiotherapy-decision
por: Xu, Biaoxiang, et al.
Publicado: (2022) -
The survival impact of radiotherapy on synchronous metastatic rectal cancer: metastatic site can serve for radiotherapy-decision
por: Zhou, Yuan, et al.
Publicado: (2022) -
The main contributor to the upswing of survival in locally advanced colorectal cancer: an analysis of the SEER database
por: Li, Yuqiang, et al.
Publicado: (2019) -
A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy
por: Li, Yuqiang, et al.
Publicado: (2021)